All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @realdrbae on TikTok · 50s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @realdrbae's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Here's some unexpected side effects you may experience while taking Ozempic.
  2. 0:03I'm real Dr. Bait, TikTok's Simaglutin to your zepitide expert.
  3. 0:06You may experience longer fingernails.
  4. 0:08That's right, this goes back to the fact that these medications suppress addictive behaviors
  5. 0:12like overeating but also biting your nails.
  6. 0:14To piggyback off of that, you may experience a reduction in skin picking.
  7. 0:18Another change you might experience is craving sweets.
  8. 0:20And this may be due to your newfound freedom that you feel like you won't gain weight
  9. 0:24by eating those sweets because you're in a caloric deficit.
  10. 0:26And another thing patients tell is that even though they are a bit tired of suppress,
  11. 0:28the only thing that sounds appetizing are sweets.
  12. 0:30Let me be very clear, this is not healthy in the long term.
  13. 0:33You definitely want to supplement with high protein diet and exercise.
  14. 0:37And finally, cold intolerance.
  15. 0:38Patients swear their hands and feet are freezing due to these medications.
  16. 0:42And while we don't know for sure why that is, it may be due to the lower body fat leading
  17. 0:46to lower insulation.
  18. 0:47Did I miss something?
  19. 0:48Tell us in the comments.

@realdrbae's Ozempic side effects video, fact-checked

Jonathan Kaplan

TikTok creator

265.7K viewsWatch on TikTok

Quick answer

Semaglutide and related GLP-1 receptor agonists have documented effects on reward and appetite pathways in the brain, which may explain patient-reported changes in compulsive behaviors and food preferences beyond the drug's primary mechanism of gastric emptying and insulin modulation. Cold intolerance is a recognized but understudied patient complaint associated with significant weight loss from any cause, including GLP-1 therapy. The specific claims in this video, including nail growth and skin picking reduction, lack controlled trial evidence and should be considered anecdotal until larger observational studies or clinical trials address them directly.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 10 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @realdrbae's Ozempic side effects video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@realdrbae's Ozempic side effects video, fact-checked" from Jonathan Kaplan. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide and related GLP-1 receptor agonists have documented effects on reward and appetite pathways in the brain, which may explain patient-reported changes in compulsive behaviors and food preferences beyond the drug's primary mechanism of gastric emptying and insulin modulation.

The reason this review is not generic is the source wording and the canonical claim label "glp1 unexpected side effects on ozempic." In this clip, the useful excerpt is: "Here's some unexpected side effects you may experience while taking Ozempic." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Cold intolerance is a real and commonly reported complaint during GLP-1 therapy, but the cause is likely multifactorial, including reduced fat mass, lower metabolic rate, and changes in peripheral circulation, not insulation alone.
People who land here are usually trying to understand whether the Compounded Semaglutide claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide and related GLP-1 receptor agonists have documented effects on reward and appetite pathways in the brain, which may explain patient-reported changes in compulsive behaviors and food preferences beyond the drug's primary mechanism of gastric emptying and insulin modulation.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide and related GLP-1 receptor agonists have documented effects on reward and appetite pathways in the brain, which may explain patient-reported changes in compulsive behaviors and food preferences beyond the drug's primary mechanism of gastric emptying and insulin modulation. Cold intolerance is a recognized but understudied patient complaint associated with significant weight loss from any cause, including GLP-1 therapy. The specific claims in this video, including nail growth and skin picking reduction, lack controlled trial evidence and should be considered anecdotal until larger observational studies or clinical trials address them directly.
  • GLP-1 receptors are expressed in brain reward circuits, and studies like Klausen et al. (2022, Translational Psychiatry) support the idea that semaglutide can influence compulsive behaviors, but nail biting specifically has not been studied in any clinical trial.
  • Cold intolerance is a real and commonly reported complaint during GLP-1 therapy, but the cause is likely multifactorial, including reduced fat mass, lower metabolic rate, and changes in peripheral circulation, not insulation alone.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • GLP-1 receptors are expressed in brain reward circuits, and studies like Klausen et al. (2022, Translational Psychiatry) support the idea that semaglutide can influence compulsive behaviors, but nail biting specifically has not been studied in any clinical trial.
  • Cold intolerance is a real and commonly reported complaint during GLP-1 therapy, but the cause is likely multifactorial, including reduced fat mass, lower metabolic rate, and changes in peripheral circulation, not insulation alone.
  • Sweet cravings during GLP-1 treatment may have a pharmacological basis, not just a psychological one. Research suggests these drugs may blunt reward responses to savory foods more than to sweet foods.
  • The creator's drug name errors ('Simaglutin,' 'zepitide') are not minor. Semaglutide and tirzepatide are distinct drugs with different mechanisms, and accuracy in this space matters for patient safety.
  • High protein intake during GLP-1 therapy is backed by evidence. Westerterp-Plantenga et al. (2012, Nutrition and Metabolism) showed protein supports satiety and lean mass preservation during caloric restriction.
  • Persistent cold intolerance on a GLP-1 medication warrants a conversation with your prescriber, including consideration of thyroid function testing, since hypothyroidism can develop independently and would worsen cold sensitivity.
  • Reduction in skin picking on GLP-1 medications is plausible given the addiction-pathway research, but it has only case-report level evidence behind it and should not be presented as an established clinical finding.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @realdrbae actually say?

The creator, who goes by "real Dr. Bait" on TikTok, claimed that semaglutide (which they called "Simaglutin") produces several unexpected side effects beyond nausea and GI distress. Specifically, they said patients grow longer fingernails because GLP-1 medications "suppress addictive behaviors like overeating but also biting your nails." They also claimed patients stop skin picking, develop sweet cravings, and experience cold hands and feet. The cold intolerance, they suggested, comes from "lower body fat leading to lower insulation." They did close with reasonable advice to eat high protein and exercise, which deserves some credit.

One problem worth flagging upfront: the creator's name-dropping of medications was garbled. They said "Simaglutin to your zepitide" which is not a real drug name. These are not minor mispronunciations. If you're positioning yourself as a TikTok expert on these medications, getting the drug names right is a baseline expectation.

Does the science back this up?

Some of it, loosely. The addiction-suppression angle has genuine scientific interest behind it, but the specific leap to nail-biting is speculation dressed up as clinical fact. The cold intolerance claim has real patient reports behind it, but the mechanism offered is oversimplified.

GLP-1 receptors are expressed in the brain's reward circuitry, and there is published evidence that semaglutide may reduce compulsive and addictive behaviors. Klausen et al. (2022, Translational Psychiatry) reviewed GLP-1 receptor agonists and their effects on reward-driven behavior, including alcohol use and binge eating. The theory that this could extend to body-focused repetitive behaviors like nail biting is plausible, but no peer-reviewed trial has tested that specific claim. On cold intolerance, weight loss in general, not just GLP-1-driven weight loss, is associated with feeling colder. Church et al. (2009, Obesity) found that significant fat loss reduces thermogenic capacity. The lower-insulation explanation is partially correct but incomplete. Some researchers suspect peripheral vasoconstriction and shifts in metabolic rate also play a role.

What did they get wrong (or right)?

They got the addiction-behavior framing mostly right in spirit, even if the nail-biting example has zero clinical trial data behind it. Credit where it's due: the sweet cravings phenomenon is something real patients report, and the creator correctly flagged that this is not healthy long-term. That's responsible messaging.

Where they went wrong: the claim that sweet cravings come from a psychological sense of "newfound freedom" because you're "in a caloric deficit" is not grounded in pharmacology. There is actually a competing hypothesis that GLP-1 agonists blunt the reward salience of savory and high-fat foods more than sweet foods, leaving a relative preference for sweets. Berthoud et al. (2022, Appetite) discussed how GLP-1 pathways modulate hedonic eating differently across food categories. That's a more evidence-based explanation than the psychological freedom framing the creator offered.

The skin picking claim (reduction in excoriation) is the weakest link here. There are case reports and one small open-label study suggesting GLP-1 agonists may reduce body-focused repetitive behaviors, but calling this an established "side effect" overstates the evidence considerably.

What should you actually know?

GLP-1 receptor agonists have a well-documented side effect profile, and most of what this video covers sits in the "anecdotally reported, biologically plausible, but not yet confirmed in controlled trials" category. That does not mean these effects are fake. It means you should not treat a TikTok video, even one from a self-described expert, as a substitute for a conversation with a licensed prescriber.

Cold intolerance is worth taking seriously if you're on semaglutide or tirzepatide. Significant, rapid weight loss changes how your body regulates temperature. If you're freezing constantly, mention it to your provider. It may warrant checking thyroid function, since hypothyroidism can develop independently and would compound cold sensitivity.

On sweet cravings: the creator's advice to prioritize protein is genuinely good. Research by Westerterp-Plantenga et al. (2012, Nutrition and Metabolism) established that higher protein intake supports satiety and lean mass preservation during caloric restriction. If you are craving sweets on a GLP-1 medication, the answer is not to indulge because "you're in a deficit." That framing can lead to poor dietary patterns that undermine treatment outcomes.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jonathan Kaplan · TikTok creator

265.7K views on this video

Unexpected side effects on Ozempic!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1 receptors?

GLP-1 receptors are expressed in brain reward circuits, and studies like Klausen et al. (2022, Translational Psychiatry) support the idea that semaglutide can influence compulsive behaviors, but nail biting specifically has not been studied in any clinical trial.

What does the video say about cold intolerance?

Cold intolerance is a real and commonly reported complaint during GLP-1 therapy, but the cause is likely multifactorial, including reduced fat mass, lower metabolic rate, and changes in peripheral circulation, not insulation alone.

What does the video say about sweet cravings during glp-1 treatment may have a pharmacological basis,?

Sweet cravings during GLP-1 treatment may have a pharmacological basis, not just a psychological one. Research suggests these drugs may blunt reward responses to savory foods more than to sweet foods.

What does the video say about the creator's drug name errors ('simaglutin,' 'zepitide')?

The creator's drug name errors ('Simaglutin,' 'zepitide') are not minor. Semaglutide and tirzepatide are distinct drugs with different mechanisms, and accuracy in this space matters for patient safety.

What does the video say about high protein intake during glp-1 therapy?

High protein intake during GLP-1 therapy is backed by evidence. Westerterp-Plantenga et al. (2012, Nutrition and Metabolism) showed protein supports satiety and lean mass preservation during caloric restriction.

What does the video say about persistent cold intolerance on a glp-1 medication warrants a conversation?

Persistent cold intolerance on a GLP-1 medication warrants a conversation with your prescriber, including consideration of thyroid function testing, since hypothyroidism can develop independently and would worsen cold sensitivity.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jonathan Kaplan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.